Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.

Our findings revealed the use of denosumab in GCTB, prior to curettage, to possibly increase the risk of local recurrence. Together with previous reports, our finding might provide information for beneficial treatment of GCTB.